Tylenol maker Kenvue was already having a painful year before U.S. President Donald Trump and his health secretary got involved. The Trump administration’s statements have cost Kenvue some $10 billion in market value and prompted investors to steer clear of the company, for now, analysts and investors said. Kenvue’s strategic review committee is considering a broad range of options, including a sale of the company or sale or spin-off of its struggling skin health & beauty unit, people familiar with the company’s thinking said. Finding a buyer for the full company would be much harder now with several dealmakers saying the company is “unsellable” until all Tylenol claims are resolved.
Read the full article: Trump’s Tylenol Claims Limit M&A Options for Parent Company Kenvue //
Source: https://www.marketscreener.com/news/trump-s-tylenol-claims-limit-m-a-options-for-parent-company-kenvue-ce7d5ad9dc88ff27